Processa Pharmaceuticals director David Young buys $99,288 in stock
David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his ...
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $5 million (excluding any proceeds that may be received upon the ...
Processa Pharmaceuticals prices $5M at-the-market offering
Processa Pharmaceuticals (PCSA) announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s ...
Processa Pharmaceuticals首席商务官购买价值34,691美元的股票
已保存。查看收藏列表。 Processa Pharmaceuticals, Inc.（纳斯达克股票代码：PCSA）的首席商务和战略官Patrick ...
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused ...
Yahoo Finance2d
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals, Inc. HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical ...